ArradiCAN - Page 3 - review
-
Copy deck, page 3: We question the use of the middle level fairbalance, as there are efficacy and safety claims, the highest level is required. Furthermore, please use the correct terminology when referring to the warnings and precautions at least once at the beginning “immune-mediated…”
Copy deck, page 3: Please include the website that the QR code links out to
Copy deck, page 3: You cannot link out to unbranded content in a branded context. If you would like to link out to the government website or PAABceutical website it will need to be directly to the home page. Please specify if any content on the PAABceutical website is unbranded.
Copy deck, page 3: Please remove the link to the clinical trials website. We question the promotion of a clinical study that is still in progress and for off label use.
Copy deck, page 3: We question the prompt to contact medinfo for more data on the endpoints discussed. Please provide this data for our review.